BNET Industries
Market Cap:$20.2M
Last Fiscal Year Sales:$1.4M
- Public
- US
Dow Jones Description
Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.
Chief Executive OfficerHarold E. Selick
Number of Employees 31
Contact Information
1300 Seaport Blvd Ste 500
Redwood City, California 94063
(650) 474-8200
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Threshold Pharmaceuticals, Inc. THLD Reports First Quarter 2009 Financial Results
News & Analysis
Filter by
threshold pharmaceuticals inc. - All News and Analysis
Speak with other shareholders about: (AMEX: REX), (AMEX: BZI), (NASDAQ: CYTR) and (NASDAQ: THLD) .
M2 PRESSWIRE-11 April 2007-Stockwire.com: Speak with other shareholders about: (AMEX: REX), (AMEX: BZI), (NASDAQ: CYTR) and (NASDAQ: THLD) .C1994-2007 M2 COMMUNICATIONS LTD RDATE:11042007 AUSTIN, TX: A very interesting indicator to look for is where the money is flowing into. We...
LWLL is on the Move! April 11, 2007.
M2 PRESSWIRE-11 April 2007-Wall Street Capital Funding LLC: LWLL is on the Move! April 11, 2007C1994-2007 M2 COMMUNICATIONS LTD RDATE:11042007 Weston, FLA. - Wall Street News Alert's "stocks to watch" this morning are: Linkwell Corporation (OTCBB: LWLL), ViRexx Medical Corp. (AMEX:...
Speak with other shareholders about: (OTCBB: CGDF), (NASDAQ: THLD), (OTCBB: FRLE) and (OTC: NWACQ) .
M2 PRESSWIRE-28 February 2007-Stockwire.com: Speak with other shareholders about: (OTCBB: CGDF), (NASDAQ: THLD), (OTCBB: FRLE) and (OTC: NWACQ) .C1994-2007 M2 COMMUNICATIONS LTD RDATE:28022007 AUSTIN, TX - A very interesting indicator to look for is where the money is flowing into. We...
Aggressive Investors Alert! July 18, 2006.
M2 PRESSWIRE-18 July 2006-Wall Street Capital Funding LLC: Aggressive Investors Alert! July 18, 2006C1994-2006 M2 COMMUNICATIONS LTD RDATE:18072006 Weston, FLA. - Wall Street News Alert's "stocks to watch" this morning are: eNotes Systems, Inc. (OTCBB: ENSY), Threshold Pharmaceuticals, Inc. (NASDAQ:...
Aggressive Stock Investors Alert! May 24, 2006.
M2 PRESSWIRE-24 May 2006-Wall Street News Alert: Aggressive Stock Investors Alert! May 24, 2006C1994-2006 M2 COMMUNICATIONS LTD RDATE:24052006 Weston, FLA. - Wall Street News Alert's "stocks to watch" this morning are: ER Urgent Care Centers (OTC: ERUG), Threshold Pharmaceuticals, Inc. (NASDAQ:...
Threshold Files Registration Statement for Follow-On Offering
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it has filed a registration statement with the Securities and Exchange Commission covering a proposed offering of 6,250,000 shares of its common stock. The Company and selling stockholders intend to grant the underwriters the option to purchase, within 30 days from the...
Additional Resources
Bird named to Threshold Pharmamceuticals Board of Directors
Redwood City-based Threshold Pharmaceuticals announced that the company has appointed Dr. Jeffrey W. Bird to its board of directors. Dr. Bird will fill the seat held by Dr. Powell, a board member since 2001. Dr. Bird will serve as a member of both the Audit Committee and the Nominating and...
PharmaVigilant Launches Electronic Capture Database for Phase 1/2 Oncology Trial in 4 Weeks for Threshold Pharmaceuticals
WESTBOROUGH, Mass. -- PharmaVigilant announced today they launched an electronic data capture database for a Phase 1/2 oncology study in 4 weeks for Threshold Pharmaceuticals. The clinical trial design includes three separate treatment arms examining escalating doses of TH-302, Threshold's proprietary Hypoxia Activated Prodrug in combination with the following chemotherapeutic...
Research and Markets: Threshold Pharmaceuticals Inc: Premium Company Profile Contains Corporate Strategy, Value Chain Presence And SWOT Analysis
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c88514) has announced the addition of "Threshold Pharmaceuticals Inc: Premium Company Profile" to their offering. Threshold Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of drugs based on metabolic targeting, an approach that targets fundamental differences in metabolism...
BellwetherReport.com Initiates Analyst Coverage of NTRI, ENCY, THLD and MDII
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch on NYSE, NASDAQ, AMEX, TSX, TSX-Venture and US Small-Cap listedcompanies. Investors seeking unbiased research on the companies mentionedare highly encouraged to sign up to www.bellwetherreport.com for a free90-day subscription. Today we have set up interviews...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Harold E. Selick | Chief Executive Officer |
| John G Curd | President |
| Michael S. Ostrach | COO & General Counsel |
| Mark D Matteucci | Senior Vice President, Discovery Research |
| Cathleen P. Davis | Vice President, Finance and Controller |
| Kevin Kaster | Vice President, Intellectual Property |
| Mark G. Matteucci | Vice President |
| Stewart M Kroll | Vice President, Biostatistics and Clinical Operations |
| Jeff Bird | Director |
| Denise T. Powell | Senior Director, Corp Communications |
| Joel A Fernandes | Senior Director, Finance and Controller |
| Jonathan W. Simons | Director, Conferences |
| Fred Volinsky | Consultant |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| David R. Hoffmann | Member, Chair, Member |
| Wilfred E. Jaeger | Member, Member, Chair |
| William A. Halter | Member, Chair |
| Bruce C. Cazadd | Board of Directors |
| Bruce C. Cozadd | Board of Directors |
| George F. Tidmarsh | Board of Directors |
| George G.C. Parker | Board of Directors |
| Herbert Hurwitz | Board of Directors |
| Michael K Brawer | Board of Directors |
| Patrick G. Enright | Board of Directors |
| Richard F Borch | Board of Directors |
| Steven A. Everett | Board of Directors |
| Theodore J Lampidis | Board of Directors |
Harold E. "Barry" Selick, Ph.D. joined Threshold as Chief Executive Officer in June 2002. Between June 2002 and July 2007, Dr. Selick was a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc.. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for treating kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Chief Executive Officer | Current |
| Epiphany Biosciences, Inc. | Co-Founder | Current |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Threshold Pharmaceuticals, Inc. | Chairman | Current |
| Catalyst Biosciences, Inc. | Chairman | Current |
| Catalyst Biosciences, Inc. | Board of Directors | Current |
| Bionaut Pharmaceuticals Inc. | Board of Directors | Current |
| Diobex, Inc | Board of Directors | Current |
| PDL BioPharma, Inc. | Bench Scientist | Former |
| Sofinnova Ventures, Inc. | Venture Partner | Former |
| University of Pennsylvania | Ph.D. in Biology | Former |
| University of Pennsylvania | B.A. in Biophysics | Former |
Dr. Curd became the President and CMO in October 2007. Dr. Curd joins Threshold as a member of the management team and will lead the clinical development of the Company’s product development candidates and help to identify additional opportunities for Threshold. Dr. Curd joins Threshold from Novacea, Inc. where he was the president and chief medical officer since 2001. From May 2001 to December 2001, Dr. Curd served as senior vice president of Development and interim president for Vaccines at Maxygen, Inc. From June 1999 to May 2001, Dr. Curd served as executive vice president at VaxGen, Inc. From December 1991 to June 1999, Dr. Curd served in various positions, including vice president of Clinical Development, at Genentech, Inc. While at Genentech, he directed the clinical development of Herceptin®, Rituxan®, Xolair®, and Raptiva®. From 1978 to 1991, Dr. Curd served in various positions, including president of the Medical Staff at Scripps Clinical and Research Foundation, La Jolla, California. Dr. Curd holds a B.S. in chemistry from Princeton University and an M.D. from Harvard Medical School.
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | President | Current |
| Threshold Pharmaceuticals, Inc. | Chief Medical Officer | Current |
| Collabrx, Inc. | Consulting Chief Medical Officer | Current |
| Collabrx, Inc. | Board of Directors | Current |
| Maxygen, Inc. | Interim President | Former |
| VaxGen, Inc. | Executive Vice President | Former |
| Maxygen, Inc. | Senior Vice President of Development | Former |
| Harvard Medical School | M.D. | Former |
| Princeton University | B.S. In Chemistry | Former |
| Harvard Medical School | B.S. In Chemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | COO & General Counsel | Current |
| Kosan Biosciences, Inc. | president | Former |
| Chiron Technologies, Inc. | president | Former |
| Kosan Biosciences, Inc. | chief operating officer | Former |
| Neurobiological Technologies, Inc. | chief operating officer | Former |
| Neurobiological Technologies, Inc. | executive vice president | Former |
| Kosan Biosciences, Inc. | Consultant | Former |
| Brown University | B.A. | Former |
Mark joined us as Vice President of Discovery in August 2002. From 1999 to 2002, he provided medicinal chemistry consultation to several biotechnology companies including Threshold. From 1988 to 1999, he was the Director of Bioorganic Chemistry at Gilead Sciences, Inc. where he was the first scientist hired and established that company’s research program in nucleic acid targeting. He built and led an interdisciplinary team of 20 scientists and was a key player in establishing a well funded scientific collaboration between Gilead and Glaxo. During his time at Gilead, he established himself as an intellectual leader in the field of nucleic acids targeting with over 50 publications and 30 patents in the area and numerous invited presentations at international meetings. Prior to joining Gilead Sciences, Dr. Matteucci was a scientist at Genentech, Inc. There, he modernized the oligonucleotide synthesis efforts and invented the H phosphonate method of DNA synthesis. He received his B.S. from the Massachusetts Institute of Technology and Ph.D. from the University of Colorado where he co-invented the DNA synthesis technology which is the foundation of the modern “gene machine”.
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Senior Vice President, Discovery Research | Current |
| Gilead Sciences, Inc. | Director of Bioorganic Chemistry | Former |
| University of Colorado | Ph.D. | Former |
Cathleen P. Davis, the Company?s Vice President, Finance and Controller, has served as the Company?s principal financial and accounting officer since October 2006. Ms. Davis, joined the Company as Controller in July 2005. Prior to joining the Company, Ms. Davis served as Controller of Theravance Inc. from 2002 to 2005, and of ALZA Corporation from 1999 to 2002. Ms. Davis has been a Certified Public Accountant in California since 1981, and has a Bachelor of Science in Business Administration from California State University, Hayward.
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Vice President, Finance and Controller | Current |
| Theravance, Inc. | Controller | Former |
| Threshold Pharmaceuticals, Inc. | Principal | Former |
| California State University | Bachelor of Science In Business Administration | Former |
Kevin Kaster, J.D., joined Threshold in October 2002 as Vice President, Intellectual Property. From August 1998, to October 2002, he served as the Vice President, Intellectual Property, to Kosan Biosciences. Prior to that he held positions managing patent portfolios at Geron (telomerase and human embryonic stem cells), Affymax (combinatorial chemistries), and Cetus (PCR). Kevin has a J.D. from Indiana University School of Law, Indianapolis, and a B.S. in Chemistry and Molecular Biology from Vanderbilt University.
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Vice President, Intellectual Property | Current |
| Curedm, Inc | Board of Directors | Current |
| Kosan Biosciences, Inc. | Vice President, Intellectual Property | Former |
| Geron Corporation | Former | |
| Indiana University | J.D. | Former |
| Indiana University School of Law | J.D. | Former |
| Vanderbilt University | B.S. In Chemistry and Molecular Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Vice President | Current |
| Gilead Sciences, Inc. | Director of Bioorganic Chemistry | Former |
| Gilead Sciences, Inc. | scientist | Former |
| Genentech, Inc. | scientist | Former |
| University of Colorado | Ph.D. | Former |
| Massachusetts Institute of Technology | B.S. | Former |
Stewart Kroll has served as the Company’s Vice President, Biostatistics and Clinical Operations since March 2007. Mr. Kroll joined the Company as Director, Biostatistics in January 2005. Prior to joining the Company, Mr. Kroll served as Sr. Director of Biostatistics at Corixa Corporation from 2000 to 2005, and served in positions of increasing responsibility, most recently as Director of Biostatistics at Coulter Pharmaceuticals from 1997 to 2000. Mr. Kroll received a B.A. and M.A. in Mathematical Statistics from University of California Berkeley.
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Vice President, Biostatistics and Clinical Operations | Current |
| Bio Statistics | Board of Directors | Former |
| University of California, Berkeley | M.A. In Mathematical Statistics | Former |
| University of California, Berkeley | B.A. | Former |
| Organization | Position | Status |
|---|---|---|
| Theracos | Managing Director at Sutter Hill Ventures | Current |
| Sutter Hill Ventures | Managing Director | Current |
| Roxro Pharma, Inc | Managing Director of Sutter Hill Ventures | Current |
| Nugen Technologies, Inc. | Managing Director at Sutter Hill Ventures | Current |
| Three Arch Partners | General Partner | Current |
| Vivio's | Board Member | Current |
| Living Microsystems Inc | Board of Directors | Current |
| Splashpaint Creative | Board of Directors | Current |
| Naryx Pharma, Inc | Board of Directors | Current |
| Roxro Pharma, Inc | Board Member | Current |
| MacuSight Inc. | Board Member | Current |
| Threshold Pharmaceuticals, Inc. | Director | Current |
| Akarx, Inc. | Board Member | Current |
| Portola Pharmaceuticals, Inc. | Board Member | Current |
| Horizon Therapeutics, Inc. | Board Member | Current |
| Theracos | Board of Directors | Current |
| Sutter Hill Ventures | Director | Current |
| Gilead Sciences, Inc. | Senior Vice President, Business Operations | Former |
| Threshold Pharmaceuticals, Inc. | Co-Founder | Former |
| Sutter Hill Ventures | Direct Sales | Former |
| Gilead Sciences, Inc. | Board of Directors | Former |
| Idun Pharmaceuticals, Inc. | Director | Former |
| Stanford University Medical Center | MD | Former |
| Stanford University School of Medicine | M.D. | Former |
| Stanford University | BS | Former |
| Stanford University | Degree In Biological Sciences | Former |
| Stanford Company | degree in Biological Sciences | Former |
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Senior Director, Corp Communications | Current |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
Joel Fernandes, the Company’s Senior Director, Finance and Controller, has served as the Company’s principal financial and accounting officer since November 2007. Mr. Fernandes, joined the Company as Assistant Controller in April 2006. Prior to joining the Company, Mr. Fernandes served as Associate Director of Finance at Theravance Inc. from 2005 to 2006, Senior Manager of Corporate Finance at KLA-Tencor from 2002 to 2005 and Assistant Controller of ALZA Corporation from 1999 to 2002. Mr. Fernandes has been a Certified Public Accountant since 1996, and has a Masters in Accountancy from Manchester College, Indiana.
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Senior Director, Finance and Controller | Current |
| Theravance, Inc. | Associate Director of Finance | Former |
| KLA-Tencor Corporation | Senior Manager | Former |
| ALZA Corporation | Assistant Controller | Former |
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Director, Conferences | Current |
Fred Volinsky began his career as an Emergency Physician where he spent 8 years on the attending staff of Massachusetts General Hospital (MGH) and Brigham and Women's Hospital in Boston. He was one of the original faculty members of the Harvard Residency in Emergency Medicine and the Harvard Department of Emergency Medicine at MGH. While at Harvard, Volinsky developed a medical device that he licensed to Moser Medical. Dr. Volinsky continued to follow his entrepreneurial interests and co-founded Exhale Pharmaceuticals, now known as CoTherix (CTRX-Nasdaq). He left MGH in 2000 to become Managing Director of RCT BioVentures, an early stage life science fund where he was an investor in a variety of biotechnology companies including Cylene Pharmaceuticals, Catalyst BioSciences, Kerberos Proximal Solutions, Imagine Pharmaceuticals, and Arizeke Pharmaceuticals. He has held Directorships at Myometrix, Cylene Pharmaceuticals, Imagine Pharmaceuticals, Kerberos Proximal Solutions, and Catalyst Biosciences. Dr. Volinsky is a Co-Chairman of the Stanford BioBootcamp and the founder and Co-Chairman of the UCSD BioBootcamp. He is a member of the Advisory Board of the UCSD Cancer Center, the Scientific Advisory Board to the Bailard Life Science Fund, and the Clinical Advisory Board of Catalyst Biosciences. Volinsky is also a consultant to Threshold Pharmaceuticals and Diobex. Dr. Volinsky earned his medical degree at Eastern Virginia Medical School. He completed a residency in Emergency Medicine at Madigan Army Medical center and was elected as a Fellow to the American College of Emergency Physicians. Volinsky spent 6 years as a military physician and was an attending physician at Walter Reed Army Center.
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Consultant | Current |
| Diobex, Inc | Consultant | Current |
| Epiphany Biosciences, Inc. | Chairman | Current |
| Micro-Surgeon | Director | Current |
| Mass Gen Hospital | Medicine Physician | Former |
| Massachusetts General Hospital | Emergency Physician | Former |
| Kerberos Proximal Solutions, Inc. | Director | Former |
| Cylene Pharmaceuticals, Inc. | Director | Former |
| Imagine Pharmaceuticals, Inc. | Director | Former |
| Eastern Virginia Medical School | Degree | Former |
| Organization | Position | Status |
|---|---|---|
| DURECT Corporation | Director, Chairman of the Audit Committee | Current |
| ALZA Corporation | Consultant | Current |
| Threshold Pharmaceuticals, Inc. | Member, Chair, Member | Current |
| DURECT Corporation | Board of Directors | Current |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Alza Technologies Corp | Vice President | Former |
| University of Colorado | B.S. in Business Administration | Former |
Prior to cofounding Three Arch Partners, Wilf was a general partner at Schroder Ventures. Wilf began his medical career in private practice. He was subsequently recruited by Chec Medical, a venture capital backed ambulatory care startup in Seattle. Later, in 1989, following business school, he began venture investing with Phoenix Partners. He has since been an active early stage investor in numerous successful biotechnology, healthcare service, and medical device companies. He has served on the boards of many private and public healthcare companies. Wilf ranked first in his class at the University of British Columbia where he earned a BS in Biology. He received his MD from the University of British Columbia School of Medicine. He has an MBA from the Stanford Graduate School of Business.
| Organization | Position | Status |
|---|---|---|
| Three Arch Partners | Co-Founder | Current |
| Susanne Nagy | Co-Founder of Three Arch Partners and Spiration | Current |
| Spiration, Inc. | Co-Founder | Current |
| Three Arch Partners | Partner | Current |
| Threshold Pharmaceuticals, Inc. | Member, Member, Chair | Current |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Threshold Pharmaceuticals, Inc. | Member | Current |
| Phoenix Partners LP | Investor | Former |
| University of British Columbia | M.D. | Former |
| Stanford University | M.B.A. | Former |
| Stanford Graduate School of Business | MBA | Former |
| University of British Columbia | B.S. | Former |
| Organization | Position | Status |
|---|---|---|
| Arkansas.Com | Current | |
| Threshold Pharmaceuticals, Inc. | Member, Chair | Current |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Xenogen Corporation | Board of Directors | Current |
| webMethods, Inc. | Board of Directors | Current |
| Social Security Administration | Acting Commissioner | Former |
| McKinsey & Company, Inc. | Associate | Former |
| InterMune, Inc. | Board of Directors | Former |
| Akamai Technologies, Inc. | Board of Directors | Former |
| University of Oxford | master's degree in economics | Former |
| Stanford University | A.B. degree with honors and distinction in economics and political science | Former |
| Mphil | B.A. | Former |
| University of Southern Maine | member | Former |
| webMethods, Inc. | member | Former |
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Orphan Medical Inc. | Current | |
| Jazz Pharmaceuticals Inc. | Chairman | Current |
| The Nueva School | Board of Directors | Current |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Jazz' | Chief Executive Officer | Former |
| ALZA Corporation | Executive Vice President and Chief Operating Officer | Former |
| Smith Barney | Former | |
| Alza Technologies Corp | Former | |
| Johnson & Johnson | Former | |
| Cerus Corporation | Board of Directors | Former |
| Stanford University | M.B.A. | Former |
| Stanford Graduate School of Business | M.B.A. | Former |
| Yale University | Bachelor's Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Horizon Therapeutics, Inc. | Scientific Consultant | Current |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Horizon Therapeutics, Inc. | Board of Directors | Current |
| Horizon Therapeutics, Inc. | President, Chief Executive Officer & Founder | Former |
| Threshold Pharmaceuticals, Inc. | President | Current |
| GlaxoSmithKline Plc | Former | |
| El Camino Hospital | Board of Directors | Former |
| Stanford University School of Medicine | M.D. | Former |
Array
| Organization | Position | Status |
|---|---|---|
| Tejon Ranch Company | Chairman | Current |
| Tejon Ranch Company | Director | Current |
| Converium Holding AG | Director | Current |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Continental Airlines, Inc. | Board of Directors | Current |
| Scor Holding (Switzerland) Ltd | Former | |
| Stanford University | Ph.D. | Former |
| Stanford University | M.B.A. | Former |
| Haverford College | B.A. | Former |
Dr. Hurwitz is an Associate Professor of Medicine at Duke University Medical Center and a medical oncologist at the Duke Comprehensive Cancer Center. Dr. Hurwitz received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania, and completed an Internal Medicine residency at Michael Reese Hospital in Chicago, Illinois, and an Oncology fellowship at Johns Hopkins Oncology Center in Baltimore, Maryland. His clinical expertise is in the areas of Phase 1 clinical trials involving new anti cancer drugs, drug combinations, and combinations of new drugs with radiation and cancers of the gastrointestinal system. His particular interest is in biomarkers related to anti-angiogenesis therapy. He was the lead author on the IFL/bevacizumab study in colorectal cancer. He is associate professor of medicine and the clinical director of the Phase 1 program and co-leader of the GI Oncology program at Duke University Medical Center in Durham, North Carolina. He is an author of over 50 peer-reviewed scientific papers published in leading journals.
| Organization | Position | Status |
|---|---|---|
| Duke University Medical Center | Clinical Director | Current |
| Duke University Medical Center | Co-Leader | Current |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Jefferson Medical College of Thomas Jefferson University | Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Tmm Clan | Dr. Brawer Is Chief Executive Officer of Uridea In Seattle | Current |
| University of Washington | Professor of Urology | Current |
| Pcaw | Current | |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Medreviews | Board of Directors | Current |
| Threshold Pharmaceuticals, Inc. | Chief Medical Officer | Former |
| Stanford University School of Medicine | Residency | Former |
| University of California School of Medicine | Medical Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Pequot Capital Management Inc. | Managing Director | Current |
| Prestwick Pharmaceuticals, Inc | General Partner, Vivo Ventures | Current |
| Tenex Greenhouse Ventures | Operating Committee | Current |
| Horizon Therapeutics, Inc. | Board of Directors | Current |
| Raven Biotechnologies, Inc. | Board of Directors | Current |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Diobex, Inc | Board of Directors | Current |
| Codexis, Inc. | Board of Directors | Current |
| Map Pharmaceuticals, Inc. | Board of Directors | Current |
| Sequenom, Inc. | Board of Directors | Current |
| Urigen Pharmaceuticals, Inc. | Board of Directors | Current |
| Corcept Therapeutics Incorporated | Member of the Board of Directors | Current |
| Biocatalytics, Inc. | Board of Directors | Current |
| Urigen Pharmaceuticals, Inc. | Cfo | Former |
| Boehringer Mannheim Corporation | Senior Vice President | Former |
| Urigen Pharmaceuticals, Inc. | Senior Vice President, Corporate Development | Former |
| PaineWebber, Inc. | Vice President | Former |
| Pequot Ventures | Managing Director | Former |
| Pequot Ventures | General Partner | Former |
| Sandoz | Strategic Planning and Business Development | Former |
| Pequot Capital Management Inc. | Principal | Former |
| Centocor, Inc. | Former | |
| Alkermes, Inc. | Former | |
| Cephalon, Inc. | Former | |
| Boehringer Mannheim | Former | |
| Amgen Inc. | Former | |
| Genentech, Inc. | Former | |
| Stanford University | M.B.A. | Former |
| Wharton School, University of Pennsylvania | M.B.A | Former |
| Stanford University | B.S. In Biological Sciences | Former |
Dr. Borch is the Head of the Department of Medicinal Chemistry and Molecular Pharmacology and is also Professor of Medicinal Chemistry and Molecular Pharmacology. He trained first at Columbia for his Ph.D., then at Harvard for as a postdoctoral fellow and then at University of Minnesota for his M.D. He is a leader in the medicinal chemistry of prodrugs and their application to targeting cancer. His early publications on hypoxia activated prodrugs have served as a foundation for the field. He has published over 100 papers.
| Organization | Position | Status |
|---|---|---|
| Medicinal Chemistry | Head of the Department | Current |
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
Dr. Everett is an Adjunct Professor of Pharmaceutical Chemistry at UCSF, Head of the Drug Discovery and Translational Research Group at the University of Dundee, and Co-Founder and Chief Scientific Officer of SPEAR Therapeutics, Inc. He has 17 years experience in the discovery and development of prodrugs for targeted cancer therapy, successfully bridging the academic and commercial interface in the field. In 1992 Dr Everett joined the Gray Laboratory a world-renowned center for radiation chemistry and biology applied to oncology which recently evolved into the Gray Institute for Radiation Oncology and Biology affiliated to the University of Oxford (UK) where he specialized in free radical mechanisms of oxidative stress in cancer and hypoxia-activated prodrug (HAP) design. In 2005 he became a principal investigator on a Cancer Research UK-funded program of research at the University of Dundee to develop innovative prodrug strategies for the treatment of cancer. Dr Everett Co-Founded SPEAR Therapeutics in 2003 and raised a significant venture capital investment in late 2005 to develop novel prodrug therapies into the clinic. In 2009 he joined the Faculty at UCSF and is a consultant on the Threshold Pharmaceutical HAP program. Dr. Everett received his doctorate in chemistry from the University of Ulster (UK) and the Hahn-Meitner Institut in Berlin (Germany) in 1991, and a Masters in Business Administration with distinction in 1997. Dr. Everett is an author of over 50 peer-reviewed scientific papers published in leading journals and 6 patents.
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Threshold Pharmaceuticals, Inc. | Board of Directors | Current |
| University of Miami | Professor of Cell Biology and Anatomy | Former |
Executive News
-
OTCPicks.com: OTCPicks.com Stocks to Watch for Friday, June 26th NPWS, AFTC, CAEI, JAZZ, CHDO
-
Jazz Pharmaceuticals and UCB announce second Phase III study of sodium oxybate in patients with fibromyalgia meets
-
Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in...
-
Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With...
-
Jazz Pharmaceuticals and UCB announce second Phase III study of
-
Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
-
Threshold Pharmaceuticals Presents Encouraging Data From Clinical Trials of TH-302...
Industry Transcripts by Seeking Alpha
-
BMP Sunstone Corporation Q1 2009 Earnings Call Transcript
on Jun 30, 2009about BJGP
-
Matrixx Initiatives, Inc., F4Q09 (Qtr End 03/31/09) Earnings Call Transcript
on May 12, 2009about MTXX
-
King Pharmaceuticals Inc., Q1 2009 Earnings Call Transcript
on May 11, 2009about KG
-
Flamel Technologies SA Q1 2009 Earnings Call Transcript
on May 11, 2009about FLML
-
Sucampo Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
on May 08, 2009about SCMP
Glass Door
IndustryTop Rated
- AstraZeneca's Seroquel Research Director Confessed to Sex-for-Studies Affairs 17 votes
- Forest Labs' Lexapro Flap Over JAMA Article Will Likely Be Examined by the Feds 11 votes
- Medarex Execs Got 10% Pay Raise Despite Delivering Nothing 11 votes
- Pfizer District Sales Manager Guilty of Altering Off-Label Celebrex Documents 10 votes
- Gilead Whistleblower Suit: A Bullet Dodged 10 votes
